Doxazosin and combination therapy reduced nocturia more than placebo, but the net benefit of active drug compared to placebo was often modest with a net difference of less than 0.20 fewer nightly nocturia episodes at 1 and 4 years. Findings in men 70 years old or older were similar, with an even smaller effect observed for finasteride.

No abstract

OBJECTIVES Describe prevalence of diabetes mellitus among centenarians. DESIGN Cross-sectional, population-based. SETTING 44 counties in northern Georgia. PARTICIPANTS 244 centenarians (aged 98-108, 15.8% men, 20.5% African-American, 38.0% community-dwelling) from the Georgia Centenarian Study (2001-2009). MEASUREMENTS Nonfasting blood samples assessed HbA1c and relevant clinical parameters. Demographic, diagnosis, and diabetes complications covariates were assessed. RESULTS 12.5% of centenarians were known to have diabetes. Diabetes was more prevalent among African-Americans (27.7%) than Whites (8.6%, p=.0002). There were no differences between men (16.7%) and women (11.7%, p=.414), centenarians living in the community (10.2%) or facilities (13.9%, p=.540). Diabetes was more prevalent among overweight/obese (23.1%) than non-overweight (7.1%, p=.002) centenarians. Anemia (78.6% versus 48.3%, p=.004) and hypertension (79.3% versus 58.6%, p=.041) were more prevalent among centenarians with diabetes than without and centenarians with diabetes took more nonhypoglycemic medications(8.6 versus 7.0, p=.023). No centenarians with hemoglobin A1c < 6.5% had random serum glucose levels above 200 mg/dl. Diabetes was not associated with 12 month all-cause mortality, visual impairment, amputations, cardiovascular disease or neuropathy. 37% of centenarians reported onset before age 80 (survivors), 47% between 80 and 97 years (delayers) and 15% age 98 or older (escapers). CONCLUSION Diabetes is a risk factor for cardiovascular disease and mortality, but is seen in persons who live into very old age. Aside from higher rates of anemia and use of more medications, few clinical correlates of diabetes were observed in centenarians.

The purpose of this paper is to examine effects of ®nasteride 5 mg across different age groups in an ethnically diverse population of men with symptomatic benign prostatic hyperplasia (BPH) seen in community urology and primary care practices.Data were combined from two previous placebo-controlled randomised trials of ®nasteride that evaluated changes in urinary symptoms, blinded global assessments of urologic status, adverse experiences, and effects on dihydrotestosterone (DHT) and prostate-speci®c antigen (PSA) in over 4500 men.Finasteride showed a favourable ef®cacy and tolerability pro®le in this large ethnically diverse population and was similarly effective in middle-aged and older men with BPH and prostate gland enlargement.

CONCLUSIONS: Sildenafil taken daily improves urinary symptoms, but not Omax. in men with ED and LUTS associated with BPH.A substantial proportion of men taking sildenafil (73%) improved from having severe LUTS before treatment to having mild or moderate LUTS after 12 weeks of nightly treatment with sildenafil. The improvement in LUTS correlated with improvement in EF domain scores, and the magnitude of IPSS improvement for men with moderate or severe LUTS appears to be comparable to that achieved with a-blockers and 5-areductase inhibitors.